$TSLA will be the PLAY OF THE DECADE when it takes out $300 with volume.
Mark that level. Watch the reaction.
DON'T FORGET: conviction is built below resistance, not above it.
$MRK — Keytruda drives roughly half of Merck’s revenue, yet growth is slowing. Moderna’s Phase 3 cancer vaccine win could change that dynamic: the vaccine is used with Keytruda, potentially strengthening its role in future combination cancer treatments.
$ABCL offering priced at $9.75 — oversubscribed with barely any discount, clear sign of strong demand. Only ~6.7% dilution, cash balance now over $750M. Solid position 💪
$MSTR
Big move incoming as it tests this "must hold" zone.
Under $1,380 and things could get ugly fast.
Earnings this week — the numbers will tell the story.
Watching closely.